

Original Research Article

Anti-amyloidogenic effect of menaquinone-7 on beta-amyloid production and aggregation

Chung-Hyun Lee¹, Eun-Sang Jo¹, Ji-Yun Yeo¹, Seong Jun Choi², Kwang Woo Hwang^{2*}, So-Young Park¹

¹Laboratory of Pharmacognosy, College of Pharmacy, Dankook University, Cheonan 31116, ²Department of Global Innovative Drugs, College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea

*For correspondence: Email: khwang@cau.ac.kr; Tel: +82 2 820 5597

Sent for review: 1 January 2021

Revised accepted: 6 January 2022

Abstract

Purpose: To investigate the beneficial effects of menaquinone-7 (MK-7), an isoform of vitamin K₂, against beta-amyloid (A β) production and aggregation in Alzheimer's disease using in vitro assays.

Methods: The cytotoxicity of MK-7 was determined by MTT assay. The amount of A β produced and secreted into the supernatant by APP-CHO cells treated with MK-7 was evaluated by ELISA. The expression of β -secretases and ADAM10, a representative α -secretase, was determined using western blot analysis. The production of sAPP β and sAPP α fragments generated by β -secretases and α -secretase, respectively, were also determined by western blot analysis. The effect on A β aggregation was assessed using Thioflavin T (Th T) assay.

Results: MK-7 (up to 75 nM) significantly decreased A β production in APP-CHO cells. This was accompanied by decreased expression of β -secretase and lower production of sAPP β ($p < 0.05$). However, expression of ADAM10 and production of sAPP α were not significantly affected. In contrast, MK-7 significantly decreased A β aggregation in a dose-dependent manner ($p < 0.05$).

Conclusion: MK-7 exerts anti-amyloidogenic effects via decreased production and lower aggregation of A β into oligomers and fibrils. Therefore, dietary supplementation with MK-7 may be beneficial for the prevention of Alzheimer's disease.

Keywords: Menaquinone-7, Beta-amyloid, β -Secretases, Aggregation, Alzheimer's disease, Vitamin K₂

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Vitamins are a class of organic compounds which function in diverse biological activities and are needed in minute quantities. Often, vitamins are not synthesized in sufficient amounts and must be supplemented through food. Vitamin K functions as a cofactor for enzymes carboxylating vitamin K-dependent proteins [1].

The two major naturally occurring vitamin Ks are vitamin K₁ and vitamin K₂ [2]. Vitamin K₁, also known as phyloquinone, has only 1 type and is produced by plants, whereas vitamin K₂, also known as menaquinone (MKn), has 14 forms and synthesized by animals and bacteria [3,4]. Although MK-4 and MK-7 are the most common forms of vitamin K₂, MK-7 is more effective because of its longer half-life in human serum [5].

It has been suggested that the reduced intake of vitamin K in diet is associated with a higher incidence of various diseases including osteoporosis [6], osteoarthritis [7], Parkinson's disease [8], and Alzheimer's disease [9]. However, the potential beneficial effects of vitamin K₂, particularly MK-7, in Alzheimer's disease have not been reported. Therefore, in this study, the potential beneficial effects of MK-7 on the inhibition of A β production and aggregation were examined using *in vitro* assay.

EXPERIMENTAL

Chemicals and reagents

Tetrahydrofuran (THF), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), and theoflavin T (Th T) were purchased from Sigma Aldrich (St. Louis, MO, USA). The MK-7 standard and MK-7 samples were provided by GF Fermentech (Cheongju, South Korea). Beta-amyloid (A β) was purchased from GL Biochem (Shanghai, China) and dimethyl sulfoxide was purchased from Wako Pure Chemical (Osaka, Japan).

Cell culture and cell viability

Chinese hamster ovarian (CHO) cells stably expressing amyloid precursor proteins (APP) (APP-CHO cells) were grown in RPMI1640 (Welgen, Gyeongsan, South Korea) supplemented with 10 % FBS (Equitech-BIO, Kerrville, TX, USA) including 1 mg/mL of gentamicin (Invitrogen, Waltham, MA, USA) as described previously [10]. The cytotoxicity of MK-7 was measured using the MTT assay as described previously [10].

Enzyme linked immunosorbent assay (ELISA)

The APP-CHO cells seeded in 96-well plates were treated with MK-7 (25, 50, or 75 nM) for 24 h. The amount of A β in the supernatant was measured using the Human A β 40 ELISA kit (Invitrogen) as per manufacturer's instructions.

Western blot analysis

For whole cell lysates, the cells were extracted with RIPA buffer. The protein concentration in the cell lysates and supernatants was determined using the Bradford Assay Kit (Bio-Rad, Hercules, CA, USA). Equal amounts of proteins for each cell lysate and supernatant sample (30 μ g) were separated on 7.5 % polyacrylamide gels using denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were electrotransferred onto an

Immobilon-P PVDF membrane (Millipore, Burlington, MA, USA) for 30 min using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). After blocking the membrane with 5 % nonfat dry milk, the membrane was incubated with primary antibody overnight at 4 °C, and then with secondary antibody (1:2000; Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for 2 h. The following antibodies were used: anti-sAPP β (1:1000; IBL-America, Minneapolis, MN, USA), anti-sAPP α (1:1,000; IBL-America, USA), anti- β -secretase (1:1000; Abcam, MA, USA), anti-ADAM10 (1:1000; Abcam, Cambridge, UK), and anti- α -tubulin (1:20,000; Sigma Aldrich). The proteins were detected by chemiluminescence using a ChemiDoc system (BioRad). Densitometric values were normalized using α -tubulin as an internal control. Western blot analysis showed that the curve was linear in the range used for each antibody.

Th T assay for the determination of A β aggregation

Beta-amyloid (1-42) solution (1 mM) was diluted in distilled water (DW) and transferred to a black 96-well plate and DW was used for blank. MK-7 solution or DW was added to the A β solution. The plates were sealed and incubated for 24 h at 37 °C. After incubation, Th T solution (thioflavin T with 100 mM glycine, pH 8.5) was added to a final concentration of 3 μ M. The plate was incubated at 37 °C for 20 min. Fluorescence was measured at 442 nm excitation and 485 nm emission wavelengths.

Statistical analysis

All data in the text and figures are presented as mean $\pm$ standard deviation. One-way analysis of variance (ANOVA) followed by Tukey's post hoc test (SPSS version 17.0, IBM, Armonk, NY, USA) was used to determine statistical significance for two or more group comparisons. Differences were considered statistically significant at $p < 0.05$.

RESULTS

Inhibitory effect of MK-7 on production of A β

The cytotoxicity of MK-7 determined using MTT assay showed that MK-7 (up to 75 nM) did not have any significant effect on the cell viability of APP-CHO ($p < 0.05$, Figure 1 A). To elucidate the effect of MK-7 on the production of A β , the amount of A β released into the supernatant from APP-CHO cells was determined using ELISA. As shown in Figure 1 B. MK-7 reduced A β

production in a dose-dependent manner. In particular, treatment of APP-CHO cells with 75 nM MK-7 significantly decreased A β production to 75 % when compared to the THF-treated control group ($p < 0.05$).




Figure 1: Effect of MK-7 on the cell viability of APP-CHO cells and the production of A β from APP-CHO cells. (A) The possible cytotoxicity of MK-7 measured using MTT assay. (B) The amount of A β released into the supernatant determined using ELISA. * $p < 0.05$ vs the THF-treated control groups

Inhibitory effect of MK-7 on sAPP β and β -secretase production

As shown in Figure 2 A, the treatment of APP-CHO cells with MK-7 decreased the production of sAPP β in a dose-dependent manner. MK-7 at 50 and 75 nM significantly decreased sAPP β production ($p < 0.05$). In particular, 75 nM MK-7 treatment decreased the amount of sAPP β produced to 60 % of the THF-treated control groups ($p < 0.05$).

β -Secretase is an enzyme involved in the cleavage of APP to sAPP β and the production of A β . As shown in Figure 2 B, MK-7 decreased β -secretase expression in APP-CHO cells in a dose-dependent manner. Treatment of APP-CHO cells with 75 nM MK-7 significantly reduced β -secretase levels to 60 % of the THF-treated control group. The decrease in levels of sAPP β and β -secretase corresponded to the decreased production of A β (Figure 1 A) ($p < 0.05$).

Effect of MK-7 on sAPP α and ADAM10 production

The amount of sAPP α , a fragment of APP produced by α -secretase, secreted by APP-CHO cells into the supernatant is shown in Figure 3 A. The amount of sAPP α secreted by APP-CHO cells was not altered by treatment with MK-7 up to 50 nM. On the other hand, treatment with 75 nM of MK-7 increased the production of sAPP α compared to the THF-treated control group, however, this was not statistically significant ($p < 0.05$).

In addition, the effect of MK-7 on the level of ADAM10, a representative α -secretase, was also determined (Figure 3 B). Treatment with 25 nM MK-7 did not alter ADAM10 expression, whereas 50 and 75 nM of MK-7 increased the expression of ADAM10, but the observed changes were not statistically significant ($p < 0.05$).




Figure 2: Effect of MK-7 on the production of sAPP β and β -secretases in APP-CHO cells. (A) The level of sAPP β produced from APP-CHO cells after treatment with MK-7 for 24 h. (B) The level of β -secretases on APP-CHO cells after treatment with MK-7 for 24 h. The graph depicts the changes in the levels of sAPP β and β -secretases. * $P < 0.05$ vs the THF-treated control groups




Figure 3: Effect of MK-7 on the production of sAPP α and the expression of ADAM10 in APP-CHO cells. (A) APP-CHO cells were treated with MK-7 and the production of sAPP α . (B) The effect of MK-7 treatment on the expression of ADAM10. The graph depicts changes in the levels of sAPP α and ADAM10. * $P < 0.05$ vs THF-treated control groups

Inhibitory effect of MK-7 on A β aggregation

The aggregation of A β from monomers to oligomers and fibrils is known to induce the neurotoxicity and subsequently cause neuronal cell death. Incubation of A β solution with MK-7 decreased A β aggregation in a dose-dependent manner (Figure 4). In particular, 75 nM of MK-7 significantly decreased A β aggregation to 80 % of the THF-treated control group ($p < 0.05$).




Figure 4: Effect of MK-7 on A β aggregation. A β was incubated with MK-7 for 24 h and the level of A β aggregation determined using Th T assay. * $P < 0.05$ vs the THF-treated A β groups

DISCUSSION

Vitamin K plays a crucial role in blood coagulation and prevents abnormal bleeding. Vitamin K is also known to be beneficial in the prevention of osteoporosis [6], osteoarthritis [7], and neurodegenerative diseases, such as Alzheimer's disease [8] and Parkinson's disease [9]. Lack of vitamin K in diet is associated with age-related cognitive decline in Alzheimer's disease due to the altered sphingolipid metabolism, oxidative stress and inflammation [11]. Previous studies have shown that supplementation with vitamin K in animals improved cognitive function and decreased neuronal degradation [12]. The underlying mechanism for the protective effect of vitamin K against cognitive dysfunction is reported to be through reduction of oxidative stress [13]. Furthermore, vitamin K₂ supplementation protected rat pheochromocytoma (PC12) cells from A β -induced toxicity via the p38 MAP kinase pathway [14]. Although the beneficial effect of vitamin K against cognitive dysfunction in Alzheimer's disease has been reported, the exact role of MK-7 in the production and aggregation of A β has not been studied previously.

The aggregation of A β is one of the major causes of Alzheimer's disease. Beta-amyloid is produced by the sequential proteolytic cleavage of APP by β -secretases and γ -secretases [15]. β -secretases cleave APP into sAPP β and C99 fragments, which are then spontaneously cleaved into A β by γ -secretases. Therefore, increased production of sAPP β is indicative of increased production of A β due to the increased

activity of β -secretases [16]. On the other hand, APP can be cleaved into sAPP α and P3 by α -secretases, notably ADAM10 [17], which precludes the formation of A β . Based on the results of the present study, MK-7 has minor effects on the production of sAPP α and the activity of α -secretases. However, MK-7 significantly decreased the production of A β and sAPP β in a dose-dependent manner. This was accompanied by the decreased activity of β -secretases. These results suggest that MK-7 decrease A β production by decreasing β -secretase activity.

Menaquinone-7 decreased A β aggregation in a dose-dependent manner. Previously it was reported that vitamin K₃, menadione, significantly decreased A β aggregation via hydrophobic interactions with amino acids, such as Ser, Glu, Val, Gln, and Phe of A β , and hydrogen bonding with Lys of A β [18]. Both MK-7 and vitamin K₃ have a menadione nucleus, but the difference in structure is that MK-7 has seven isoprene units, while vitamin K₃ does not. Therefore, the inhibitory effect of MK-7 on A β aggregation could be via hydrophobic interactions or hydrogen bonding of menadione of MK-7 with amino acids of A β .

CONCLUSION

Treatment of APP-CHO cells with MK-7 significantly decreases the production of A β . This is accompanied with a decrease in production of sAPP β and expression of β -secretases, but it does not influence the production of sAPP α and expression of ADAM10. In addition, MK-7 decrease the aggregation of A β . These results suggest that MK-7 possesses anti-amyloidogenic effect by decreasing A β production via inhibition of β -secretases, and A β aggregation. Therefore, dietary supplementation of MK-7 could be beneficial for the prevention of Alzheimer's disease by decreasing A β production and reducing A β aggregation. However, these beneficial effects against Alzheimer's disease should first be confirmed using animal models.

DECLARATIONS

Acknowledgement

This research was supported by the Chung-Ang University Research Scholarship Grants in 2020, and by the Ministry of Trade, Industry, and Energy (MOTIE), Korea, under the "Regional Industry-based Organization Support Program" (no. R0004851) supervised by the Korea Institute for Advancement of Technology (KIAT).

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Chung-Hyun Lee, Eun-Sang Jo, Ji-Yun Yeo, and Seong Jun Choi performed the experiments. So-Young Park and Kwang Woo Hwang designed the study and discussed the data. Kwang Woo Hwang analyzed the data and So-Young Park supervised the experimental work. Kwang Woo Hwang revised the manuscript. All authors read and approved the final manuscript.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Dam H. The antihaemorrhagic vitamin of the chick. *Biochem J* 1935; 29: 1273-1285.
2. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, Vermeer V. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. *Z Kardiol* 2001; 90 Suppl 3: 57-63.
3. Mahdinia E, Demirci A, Berenjian A. Production and application of menaquinone-7 (vitamin K2): a new perspective. *World J Microbiol Biotechnol* 2017; 33: 2.
4. Shearer MJ. Vitamin K. *Lancet* 1995; 345: 229-234.
5. Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PHM, van der Schouw YT. A high menaquinone intake reduces the incidence of coronary heart disease. *Nutr Metab Cardiovasc Dis* 2009; 19: 504-510.
6. Villa JKD, Diaz MAN, Pizzolo VR, Martino HSD. Effect of vitamin K in bone metabolism and vascular calcification: A review of mechanisms of action and evidences. *Crit Rev Food Sci Nutr* 2017; 57: 3959-3970.
7. Shea MK, Kritchevsky SB, Hsu FC, Nevitt M, Booth SL, Kwoh CK, McAlindon TE, Vermeer C, Drumm N, Harris TB, Womack C, Loeser RF. The association between vitamin K status and knee osteoarthritis features in older adults: the Health, Aging and Body Composition Study. *Osteoarthritis Cartilage* 2015; 23: 370-378.
8. Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Meensel SV, Schaap O, Strooper BD, Meganathan R, Morais VA, Verstreken P. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. *Sci* 2012; 336: 1306-1310.
9. Ferland G. Vitamin K and the nervous system: an overview of its actions. *Adv Nutr* 2012; 3: 204-212.
10. Kang YJ, Seo DG, Park SY. Phenylpropanoids from cinnamon bark reduced beta-amyloid production by the inhibition of beta-secretase in Chinese hamster ovarian cells stably expressing amyloid precursor protein. *Nutr Res* 2016; 36: 1277-1284.
11. Ferland G. Vitamin K, an emerging nutrient in brain function. *Biofactors* 2012; 38: 151-157.
12. Crivello NA, Casseus SL, Peterson JW, Smith DE, Booth SL. Age- and brain region-specific effects of dietary vitamin K on myelin sulfatides. *J Nutr Biochem* 2010; 21: 1083-1088.
13. Li J, Wang H, Rosenberg PA. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. *J Neurosci Res* 2009; 87: 1997-2005.
14. Hadipour E, Tayarani-Najaran Z, Fereidoni M. Vitamin K2 protected PC12 cells 11 against Abeta-induced apoptosis via p38 MAP kinase. *Nutr Neurosci* 2020; 23: 343-352.
15. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. *J Neurochem* 2012; 120 Suppl 1: 9-21.
16. Park H, Yoo JS, Kim JY, Hwang BY, Han JS, Yeon S-W, Kang J-H. Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of *Melia toosendan*, through activation of the phosphatidylinositol 3-kinase/Akt pathway. *Environ Toxicol Pharmacol* 2014; 37: 513-520.
17. Park SY. Potential therapeutic agents against Alzheimer's disease from natural sources. *Arch Pharm Res* 2010; 33: 1589-1609.
18. Alam P, Chaturvedi SK, Siddiqi MK, Rajpoot RK, Ajmal MR, Zaman M, Khan RH. Vitamin k3 inhibits protein aggregation: Implication in the treatment of amyloid diseases. *Sci Rep* 2016; 6: 26759.

Copyright of Tropical Journal of Pharmaceutical Research is the property of Pharmacotherapy Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.